Saxenda in Singapore: Daily Liraglutide for Weight Management

The weight-management injections people hear most about are weekly. Liraglutide is the daily one — an older, well-studied molecule in the same class, licensed in Singapore for weight management under the brand name Saxenda, and still a reasonable option for some patients.

This article sets out what it is, who it is licensed for here, and the review rule that makes it different from the weekly options. It quotes no medicine figures, because obtaining a prescription-only medicine without a prescription is the one route with no assessment and no follow-up.

What it is

Saxenda is the brand name for liraglutide, given as a once-daily injection. It acts on the GLP-1 receptor — one of the gut hormones released after eating that influence fullness, stomach emptying, insulin release and glucagon production.

The mechanism is the same family as the weekly medicines. What differs is the dosing schedule, the titration steps, and the clinical evidence base specific to this molecule.

It is not a fat burner. It changes appetite signalling and glucose handling, and weight loss follows from eating less, sustainably.

What it is licensed for in Singapore

Liraglutide is registered with the Health Sciences Authority as a prescription-only medicine. The Singapore product information lists weight management as an indication:

Adults — as an adjunct to a reduced-calorie diet and increased physical activity, for weight management in adults with an initial BMI of:

• 30 kg/m² or above (obesity), or
• 27 to below 30 kg/m² (overweight) with at least one weight-related condition such as dysglycaemia (prediabetes or type 2 diabetes), hypertension, dyslipidaemia or obstructive sleep apnoea.

Adolescents aged 12 and above — as an adjunct to healthy nutrition and increased physical activity, for those with an inadequate response to diet and activity alone, obesity, and body weight above 60 kg, with limitations of use set out in the product information.

Weight management here is a licensed use, not an off-label one — within those thresholds, prescribed after assessment.

The 12-week checkpoint

This is the part of the label worth understanding before starting.

The product information states that treatment should be discontinued after 12 weeks at the 3.0 mg daily dose if at least 5% of initial body weight has not been lost.

That is unusually concrete for a weight-management medicine, and it is a feature rather than a restriction. Three months is enough time to tell whether a treatment is working for you. If it is not, continuing to pay for it is a decision nobody should drift into. A supervised programme builds that review into the plan from the start rather than discovering it at month six.

Who it may suit, and who it does not

May be reasonable to consider if your BMI is in the licensed range, previous attempts have not held, and you have weight-related conditions that treatment would help. The daily schedule suits some people more than a weekly injection — it is easier to adjust quickly if side effects appear, and it builds a daily routine.

Generally not appropriate if you are pregnant, planning pregnancy or breastfeeding; if you have had a serious allergic reaction to liraglutide; or with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 — both listed as contraindications. A history of pancreatitis, significant gastrointestinal disease or gallbladder problems requires a careful conversation.

What a supervised programme involves

Assessment. Weight history, previous attempts, other medicines and conditions, blood pressure, and baseline bloods where indicated.

A titration plan. The dose is increased in steps by design, because gastrointestinal tolerance is what limits how fast it can go. Knowing what the steps are, and what to do if one is uncomfortable, is most of the first month.

The 12-week review. A planned decision point with a number attached, not a vague check-in.

The maintenance plan. Appetite returns when treatment stops. The exit plan — food, activity, muscle preservation, follow-up — is designed at the start.

Side effects worth knowing about

Common: nausea, vomiting, diarrhoea, constipation and early fullness, usually settling as the dose stabilises. Injection-site reactions are more frequent with a daily injection simply because there are more injections.

Less common but more serious: pancreatitis, gallbladder problems, and muscle loss alongside fat during rapid weight reduction. Severe or persistent abdominal pain needs medical review, not patience.

The part nobody advertises

Pens bought through social media, messaging apps or unregistered sellers are supplied outside the law. You cannot verify the contents, the storage or the cold chain, and there is no clinician screening contraindications or managing side effects. Injectable medicines are not groceries.

Questions worth asking any clinic

• Is weight management a registered indication for the medicine being proposed, in Singapore?
• What is the titration plan, and who do I contact between reviews?
• What happens at the three-month review if the response is inadequate?
• What are the baseline tests, and what do they involve?
• What is the plan for stopping, and what comes after it?

Where this fits at Accord Medical

Weight management here is doctor-led and assessment-first: the medical weight loss programme starts with history and measurements. The GLP-1 guide explains the wider class, the tirzepatide explainer covers the dual-action weekly option, and the cost page lists clinic fees in full.

To talk it through, book a consultation — in clinic or by teleconsult.

---

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for medical concerns, diagnosis, or treatment. Accord Medical Clinic is an MOH-registered medical clinic in Singapore. Dr Joseph Wang (Family Physician) provides medical weight management consultations.

Medicine information referenced from the Singapore National Drug Formulary product information for Saxenda (liraglutide), registration number SIN15338P, last updated 2026.